⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
globenewswire.com
CRNX
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
globenewswire.com
CRNX
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
globenewswire.com
CRNX
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
globenewswire.com
CRNX
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
globenewswire.com
CRNX
Form 8-K
sec.gov
CRNX
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
CRNX
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
globenewswire.com
VNDA
GRFS
BHC
RDHL
MRK
TEVA
PFE
SNY
LLY
ABBV
AZN
CRCT
SPRO
CRNX
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
globenewswire.com
CRNX
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
globenewswire.com
CRNX